Progenity Provides Corporate Updates and Reports Second Quarter 2020 Financial Results Completed initial public offering raising gross proceeds of $100M Reported 75 thousand tests in the second quarter, showing resiliency of business during COVID‑19 pandemic Signed first precision...

Progenity to Report Second Quarter 2020 Financial Results SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...

Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company focused on providing complex molecular and specialized diagnostic tests to clinicians as well as...